ARRY was up 14.25% for the week ending 2/9/2018 countering the decline in the broad fiancial markets. The clinical news was good for their melanoma treatment and their were some investment upgrades mid weeks to the end of the week for ARRY.
See:
https://finance.yahoo.com/news/today-research-reports-stocks-watch-131000862.html
https://finance.yahoo.com/news/array-apos-melanoma-combo-shows-152303630.html
https://finance.yahoo.com/news/apos-why-array-biopharma-inc-205500809.html
https://www.businesswire.com/news/home/20180207005864/en/
From the Staff at BioBizNet.com |